Sorafenib (as tosylate)

Key facts

Invented name
Nexavar
Active substance
Sorafenib (as tosylate)
Therapeutic area
Oncology
Decision number
P/68/2010
PIP number
Sorafenib (as tosylate)
Pharmaceutical form(s)
Film-coated tablets
Condition(s) / indication(s)
Differentiated thyroid cancer
Route(s) of administration
Oral use
Contact for public enquiries
Applicant: Bayer Schering Pharma AG
E-mail: pediatrics.medical-affairs-europe@bayerhealthcare.com
Country: Germany
Phone: +49 3046815333
Fax: +49 3046815333
Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating